3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
21
Brain Neoplasms
9
Medulloblastoma
7
Central Nervous System Neoplasms
7
Lymphoma
6
Glioma
6
Astrocytoma
5
Oligodendroglioma
4
Recurrence
3
Gliosarcoma
3
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Ependymoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, AIDS-Related
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Familial ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Temozolomide
2
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
Vincristine
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Maintenance Chemotherapy
1
Lutetium-177
1
Lutetium
1
Lomustine
1
Interleukin-12
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Cisplatin
1
Busulfan
1
Bone Marrow Transplantation
1
Aminolevulinic Acid
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors
×
Lomustine
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled